XML 33 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Share-Based Payments (Tables)
 9 Months Ended
Jan. 31, 2025
Share-Based Payment Arrangement [Abstract]  
Schedule of Allocation Of Share Based Compensation Expense
Stock-based compensation expense was recognized as follows (table in thousands):
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2025202420252024
General and administrative$209 $272 $299 $487 
Sales and marketing31 73 122 160 
Research and development2 5 9 17 
Cost of oncology revenue14 29 93 191 
Total stock-based compensation expense$256 $379 $523 $855 
Schedule of Valuation Assumptions For Stock Options Black-Scholes assumptions used to calculate the fair value of options granted during the three and nine months ended January 31, 2025 and 2024 were as follows:
 
Three Months Ended
January 31,		Nine Months Ended
January 31,
 2025202420252024
Expected term in years
6
6
6
6
Risk-free interest rates
4.09% - 4.34%
4.49%
3.58% - 4.48%
3.95% - 4.49%
Volatility
54.54% - 56.37%
63.41%
54.54% - 62.72%
 62.83% - 63.41%
Dividend yield—%—%—%—%
Schedule of Stock Option Activity
The Company’s stock options activity for the nine months ended January 31, 2025 was as follows:
 
Directors
and
Employees		Non-
Employees		TotalWeighted
Average
Exercise
Price		Weighted
Average
Remaining
Contractual
Life (Years)		Aggregate
Intrinsic
Value
Outstanding, April 30, 20241,883,166 36,331 1,919,497 $5.04 5.2$2,172,000 
Granted280,455 — 280,455 4.49 9.7
Exercised(111,804)— (111,804)2.81 
Forfeited(213,625)— (213,625)6.50   
Canceled(3,750)— (3,750)5.99 
Expired(36,666)— (36,666)5.43   
Outstanding, January 31, 20251,797,776 36,331 1,834,107 $4.91 5.1$11,196,000 
Vested and expected to vest as of January 31, 20251,797,776 36,331 1,834,107 $4.91 5.1$11,196,000 
Exercisable as of January 31, 20251,561,755 5,625 1,567,380 $4.92 4.4$9,571,000